CCM
SUPN icon

Catalio Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Catalio Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,019
Closed -$3.21M – 49
2026
Q1 		$3.21M Sell
62,019
-195,446
-76% -$9.95M 0.67% 30
2025
Q4 		$12.8M Sell
257,465
-29,625
-10% -$1.44M 2.26% 19
2025
Q3 		$13.7M Buy
+287,090
New +$11.6M 2.54% 17

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Catalio Capital Management's SUPN Position: Q2 2026 in Review

Catalio Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 62,019 shares — an estimated $3.21M sold.

Catalio Capital Management first reported a position in SUPN in Q3 2025 and held it in 3 quarters. The position peaked at $13.7M in Q3 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Catalio Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Catalio Capital Management sold 62,019 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.21M.
  • Catalio Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Catalio Capital Management's Supernus Pharmaceuticals position peaked at $13.7M in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.